Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...

Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in ...

In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for approximately $14.6 billion, paying $132 per share in cash. The acquisition includes CAPLYTA® (lumateperone), the ...

Intra-Cellular Therapies, Inc. recently disclosed its entry into an Agreement and Plan of Merger with Johnson & Johnson, a New Jersey corporation, along with Fleming Merger Sub, Inc., a Delaware ...

In the preceding three months, 6 analysts have released ratings for Intra-Cellular Therapies ITCI, presenting a wide array of perspectives from bullish to bearish. The table below provides a ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...

On 13 January 2024, Johnson & Johnson (J&J) announced the acquisition of Intra-Cellular Therapies, a biopharmaceutical company specialising in developing treatments targeting complex psychiatric ...

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.